Related Experiment Video
Updated: Mar 10, 2026
Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody
Published on: May 16, 2020
Antibody-siRNA conjugates: drugging the undruggable for anti-leukemic therapy
1a Laboratory of Novel Biologics, Department of Biochemistry & Molecular Genetics , University of Virginia Cancer Center, University of Virginia School of Medicine , Charlottesville , VA , USA.
Introduction:
Generating effective RNAi-based therapies with the potential to achieve leukemia remission remains critical unmet need. Despite a growing number of leukemia clinical trials, tissue specific delivery of therapeutic siRNA is a major roadblock in translating its clinical potential. The most recent reports in the antibody-siRNA-conjugates (ARCs) field add new dimensions to leukemic therapy, where a covalently ligated therapeutic antisense-RNA with the potential to repress the oncogenic transcript is selectively delivered into the cancer cells. Despite ARC localization to leukemic cells due to high affinity antigen-antibody interactions, multiple challenges exist to unlock the therapeutic potential of siRNA targeting. Areas covered: This review focuses on antibody and siRNA-based therapies for leukemia as well as potential antibody engineering-based strategies to generate an optimal ARC platform. Expert opinion: In vitro and clinical results have revealed that non-targeted delivery and inefficient cellular internalization of therapeutic siRNA are major contributing factors for the lack of efficacy in leukemia patients. Rational antibody design and selective protein engineering with the potential to neutralize siRNA charge, stabilize ARC complex, restrict off-targeted delivery, optimize endosomal escape, and extend serum half-life will generate clinically relevant leukemic therapies that are safe, selective, and effective.
Insights
Developing targeted RNA interference (RNAi) therapies for leukemia is crucial. Antibody-siRNA conjugates (ARCs) show promise for selective delivery, but overcoming delivery challenges is key for effective leukemia treatment.
Area of Science:
- Oncology
- Molecular Biology
- Biotechnology
Background:
- Effective RNA interference (RNAi) therapies for leukemia are needed, but tissue-specific delivery of small interfering RNA (siRNA) remains a significant challenge.
- Antibody-siRNA conjugates (ARCs) offer a strategy for targeted delivery of therapeutic RNA to cancer cells.
- Current ARC approaches face challenges in cellular internalization and off-target effects, limiting therapeutic efficacy.
Purpose of the Study:
- This review focuses on antibody and siRNA-based therapies for leukemia.
- It explores antibody engineering strategies to create optimal ARC platforms for leukemia treatment.
- The goal is to identify approaches to enhance the clinical potential of siRNA-based leukemia therapies.
Main Methods:
- Review of current literature on antibody and siRNA therapies for leukemia.
- Analysis of antibody engineering strategies for ARC development.
- Evaluation of challenges and potential solutions for siRNA delivery in leukemia.
Main Results:
- Non-targeted delivery and inefficient cellular uptake of siRNA contribute to the lack of efficacy in leukemia patients.
- ARC localization to leukemic cells is achieved through antigen-antibody interactions.
- Multiple challenges hinder the full therapeutic potential of siRNA targeting in leukemia.
Conclusions:
- Rational antibody design and protein engineering are essential for developing effective ARCs.
- Strategies to neutralize siRNA charge, stabilize complexes, and optimize delivery are critical.
- Improved ARC platforms promise safer, more selective, and effective leukemia therapies.
More Related Videos
10:46A Flow Cytometry-Based Cell Surface Protein Binding Assay for Assessing Selectivity and Specificity of an Anticancer Aptamer
Published on: September 13, 2022
11:58Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting
Published on: March 8, 2018
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:30siRNA - Small Interfering RNAs
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...